Your browser doesn't support javascript.
loading
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act.
Chambers, James D; Clifford, Katherine A; Enright, Daniel E; Neumann, Peter J.
Affiliation
  • Chambers JD; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
  • Clifford KA; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
  • Enright DE; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
  • Neumann PJ; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
JAMA Netw Open ; 6(8): e2329006, 2023 08 01.
Article in En | MEDLINE | ID: mdl-37581890
This cohort study assesses rates at which orphan drugs approved by the US Food and Drug Administration were also approved for supplemental (follow-on) indications.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Orphan Drug Production / Drug Approval Type of study: Observational_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: JAMA Netw Open Year: 2023 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Orphan Drug Production / Drug Approval Type of study: Observational_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: JAMA Netw Open Year: 2023 Document type: Article Country of publication: United States